FDA advisors unanimously vote to approve Moderna's mRNA after agency drama

In February, a Trump official refused to review the vaccine.

The short version

• In February, a Trump official refused to review the vaccine..
• In an all-day meeting, members of the FDA’s advisory committee—known as VRBPAC for Vaccines and Related Biological Products Advisory Committee—pored over data and presentations on the vaccine, which is dubbed mRNA-1010 and branded as mFlusiva.
• The presentations included a review from FDA scientists, which was supportive of the vaccine.

Key context

“I think that the studies that were presented today were very well conducted,” VRBPAC voting member Flor Munoz-Rivas, a pediatric infectious disease expert at Baylor College of Medicine, said after the vote.

What to watch

“They have very clear results that are very robust in terms of demonstrating that additional efficacy.” Prasad was pushed out of FDA at the end of April amid a string of decried decisions and controversies.